SCH-018908 - RIBAVIRIN: payments to doctors
Payments that named SCH-018908 - RIBAVIRIN as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Merck?
Merck reported the most payments naming SCH-018908 - RIBAVIRIN. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $13K
- Providers
- 2
- Transactions
- 4
- Average per transaction
- $3,313
The per-transaction average — $3,313 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 2 providers the average total is $6,625, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Merck | $13,250 | 100.0% |
Other products from Merck
The company that reported the most payments naming SCH-018908 - RIBAVIRIN also reports against these.